Medical device executive John T Kilcoyne has been appointed as chief executive officer of JenaValve Technology, effective immediately. In addition, he will serve as a member of the board of directors.
Kilcoyne is a proven leader in the medical device industry. He has broad and applicable experience leading high-tech medical device emerging growth organisations through market approvals, market access, high growth and successful strategic transactions, including IPOs and M&A activities.
Prior to joining JenaValve, Kilcoyne served as President and CEO of ReVision Optics. From 2004 to 2010, he was President and CEO at Micrus Endovascular Corporation where he led an IPO in 2005, the capture of significant market share and, ultimately, the acquisition by Johnson & Johnson in 2010. He also held CEO positions at medical device companies Solace Therapeutics from 2002 to 2004 and Endonetics, which he joined in 1997 and was acquired by Medtronic in 2001.
“I am thrilled that John Kilcoyne has agreed to lead our company. In John, we have identified a dynamic and seasoned executive with an extensive background in driving medical businesses through the key stages of growth and value generation,” said Jan Keltjens, chairman of the board.
Kilcoyne said, “I am pleased to have the opportunity to lead JenaValve, and I look forward to working with the team to bring new, innovative solutions to the transcatheter valve market. Data from past and ongoing trials clearly indicate the strong potential that the JenaValve technology can greatly improve the health of patients with aortic stenosis and aortic regurgitation. Our focus in 2019 is on completing the current clinical development programs and gaining commercial readiness for potential international launch activities under CE mark and US Humanitarian Device Exemption regulatory processes.”
Kilcoyne replaces Victoria Carr-Brendel who left the company to accept another leadership role in the fourth quarter 2018. Keltjens commented, “Victoria made many significant contributions during her tenure at JenaValve. We are grateful for her contributions and wish her well in her future endeavors.”